MX2007007206A - Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos. - Google Patents
Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos.Info
- Publication number
- MX2007007206A MX2007007206A MX2007007206A MX2007007206A MX2007007206A MX 2007007206 A MX2007007206 A MX 2007007206A MX 2007007206 A MX2007007206 A MX 2007007206A MX 2007007206 A MX2007007206 A MX 2007007206A MX 2007007206 A MX2007007206 A MX 2007007206A
- Authority
- MX
- Mexico
- Prior art keywords
- agonist
- prevention
- treatment
- neurodegenerative disorders
- patient
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63576604P | 2004-12-14 | 2004-12-14 | |
| PCT/US2005/044820 WO2006065710A1 (en) | 2004-12-14 | 2005-12-12 | Use of a 5-ht6 agonist for the treatment and prevention of neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007007206A true MX2007007206A (es) | 2008-03-26 |
Family
ID=36177731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007007206A MX2007007206A (es) | 2004-12-14 | 2005-12-12 | Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20060128744A1 (enExample) |
| EP (1) | EP1824464A1 (enExample) |
| JP (1) | JP2008523146A (enExample) |
| KR (1) | KR20070088770A (enExample) |
| CN (1) | CN101098683A (enExample) |
| AU (1) | AU2005316675A1 (enExample) |
| BR (1) | BRPI0519036A2 (enExample) |
| CA (1) | CA2590841A1 (enExample) |
| CR (1) | CR9200A (enExample) |
| IL (1) | IL183859A0 (enExample) |
| MX (1) | MX2007007206A (enExample) |
| NO (1) | NO20073104L (enExample) |
| RU (1) | RU2007122450A (enExample) |
| WO (1) | WO2006065710A1 (enExample) |
| ZA (1) | ZA200705083B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200301251A (en) * | 2001-12-20 | 2003-07-01 | Wyeth Corp | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
| JP2005305107A (ja) * | 2004-03-25 | 2005-11-04 | Sei Matsuoka | 価値的情報値の測定装置およびこれを使用した測定方法 |
| US8604031B2 (en) | 2006-05-18 | 2013-12-10 | Mannkind Corporation | Intracellular kinase inhibitors |
| EP1953153A1 (en) * | 2007-01-31 | 2008-08-06 | Laboratorios del Dr. Esteve S.A. | Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders |
| US8252821B2 (en) * | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| CN104276993B (zh) * | 2013-07-12 | 2019-03-15 | 广东东阳光药业有限公司 | 吲哚衍生物及其在药物上的应用 |
| CN104557664B (zh) * | 2013-10-19 | 2020-01-21 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物上的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9820113D0 (en) * | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
| DK1455779T3 (da) * | 2001-12-20 | 2006-10-30 | Wyeth Corp | Indolylalkylaminderivater som 5-hydroxytryptamin-6-ligander |
| UA78999C2 (en) * | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
-
2005
- 2005-12-12 BR BRPI0519036-3A patent/BRPI0519036A2/pt not_active IP Right Cessation
- 2005-12-12 RU RU2007122450/14A patent/RU2007122450A/ru not_active Application Discontinuation
- 2005-12-12 MX MX2007007206A patent/MX2007007206A/es unknown
- 2005-12-12 CN CNA2005800464202A patent/CN101098683A/zh not_active Withdrawn
- 2005-12-12 CA CA002590841A patent/CA2590841A1/en not_active Abandoned
- 2005-12-12 EP EP05853687A patent/EP1824464A1/en not_active Withdrawn
- 2005-12-12 JP JP2007546799A patent/JP2008523146A/ja not_active Withdrawn
- 2005-12-12 WO PCT/US2005/044820 patent/WO2006065710A1/en not_active Ceased
- 2005-12-12 KR KR1020077015556A patent/KR20070088770A/ko not_active Withdrawn
- 2005-12-12 AU AU2005316675A patent/AU2005316675A1/en not_active Abandoned
- 2005-12-13 US US11/301,445 patent/US20060128744A1/en not_active Abandoned
-
2007
- 2007-06-12 IL IL183859A patent/IL183859A0/en unknown
- 2007-06-13 ZA ZA200705083A patent/ZA200705083B/xx unknown
- 2007-06-18 NO NO20073104A patent/NO20073104L/no not_active Application Discontinuation
- 2007-06-20 CR CR9200A patent/CR9200A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1824464A1 (en) | 2007-08-29 |
| KR20070088770A (ko) | 2007-08-29 |
| JP2008523146A (ja) | 2008-07-03 |
| CA2590841A1 (en) | 2006-06-22 |
| NO20073104L (no) | 2007-07-02 |
| RU2007122450A (ru) | 2009-01-27 |
| WO2006065710A1 (en) | 2006-06-22 |
| CR9200A (es) | 2007-09-07 |
| CN101098683A (zh) | 2008-01-02 |
| IL183859A0 (en) | 2008-12-29 |
| ZA200705083B (en) | 2010-03-31 |
| US20060128744A1 (en) | 2006-06-15 |
| BRPI0519036A2 (pt) | 2008-12-23 |
| AU2005316675A1 (en) | 2006-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200602048A (en) | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of β -secretase | |
| IL182417A0 (en) | Mitotic kinesin inhibitors and methods of use thereof | |
| TW200602045A (en) | Amino-5, 5-diphenylimidazolone derivatives for the inhibition of β-secretase | |
| TW200612926A (en) | Compounds and compositions as ppar modulators | |
| TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
| MX2009009491A (es) | Compuestos y composiciones como moduladores de la actividad del gpr119. | |
| MY162067A (en) | Combination therapy for treatment of patients with neurological disorders and cerebral infarction | |
| WO2009009417A3 (en) | Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion | |
| IL186707A (en) | Mitotic quinine inhibitors and medical preparations containing them | |
| MXPA05012358A (es) | Combinacion farmaceutica que comprende modafinilo y otra droga. | |
| TW200505443A (en) | Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases | |
| NO20073104L (no) | Anvendelse av en 5-HT6 agonist for behandling og forebygging av neurodegenerative forstyrrelser | |
| WO2008016640A3 (en) | Use of poloxamer for the prevention and/or treatment of heart failure | |
| IL193799A0 (en) | New therapeutic combinations for the treatment or prevention of psycotic disorders | |
| WO2004093813A3 (en) | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders | |
| MXPA05011699A (es) | Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior. | |
| UA96926C2 (ru) | Применение sdf-1 для лечения и/или профилактики неврологических заболеваний | |
| PL377732A1 (pl) | Nowa synergistyczna kombinacja zawierająca roflumilast i formoterol | |
| WO2005092062A3 (en) | Compounds for neurodegenerative disorders | |
| MX2010003615A (es) | Tratamiento de desordenes neurologicos. | |
| TW200501958A (en) | A therapeutic agent for treating a behavioral disorder | |
| TNSN06381A1 (en) | Compounds and compositions as ppar modulators | |
| TW200603791A (en) | Compounds and compositions as cathepsin S inhibitors | |
| TW200635580A (en) | Methods of treatment and prevention | |
| ATE468852T1 (de) | Lofexidine zur intraspinalen anwendung |